Low-Dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: A randomized controlled trial

HIV Clinical Trials

Volumn 1, Issue 3, 2000, Pages 1-15

  Lalezari, Jacob P ^a   Beal, Jeffrey A ^b   Ruane, Peter J ^c   Cohen, Calvin J ^d   Jacobson, Elizabeth L ^e   Sundin, David ^f   Pharm, D ^f   Leong, F Wai Ping ^f   Raffanti, Stephen P ^g   Wheeler, David A ^h   Anderson, Roger D ⁱ   Keiser, Philip ^j   Schrader, Shannon R ^k   Jeffrey Goodgame, C ^l   Steinhart, Corklin R ^m   Murphy, Robert L ⁿ   Wolin, Maurice J ^f   Smith, Kendall A ^e  

^a Quest Clinical Research   (United States)

^b Associates in Medical and Mental Health   (United States)

^c Tower Infectious Diseases Medical Associates ^*  (United States)

^d Community Research Initiative ^*  (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

^g Comprehensive Care Center ^*  (United States)

^h Infectious Diseases Physicians   (United States)

ⁱ Anderson Clinical Research   (United States)

^j UNIVERSITY OF TEXAS   (United States)

^k Southampton Medical Group   (United States)

^l Central Florida Research Initiative   (United States)

^m Mercy Hospital Miami   (United States)

ⁿ NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

Human immunodeficiency virus; Interleukin 2

Indexed keywords

INTERLEUKIN 2;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; VIROLOGY; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; MALE; MIDDLE AGED; VIRAL LOAD;

EID: 0034331263     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/T5FR-8JPX-0NEF-XDKD     Document Type: Article

References (19)

1. Connors M, Kovacs JA, Krevat S, et al. HIV infection induces changes in CD4+ T cell phenotype and depletions within the CD4+ T cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med. 1997;3:533-540.
2. Pakker NG, Notermans DW, De Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation. Nat Med. 1998;4:208-214.
3. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostatis and function in advanced HIV disease. Science. 1997;277:112-116.
4. Mor F, Walker BD, Rosenberg R, Kalams S. Helper CD4+ T cells and HIV-1 [letter]. Science. 1998;279:1436.
5. Smith KA. Interleukin-2: Inception, impact, and implications. Science. 1988;240:1169-1176.
6. Herberman RB. Augmentation of NK cell activity by IL-2. Prog Clin Biol Res. 1987;244:267-274.
7. Meropol NJ, Barresi GM, Fehniger TA, Hitt J, Franklin M, Caligiuri MA. Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunol Immunother. 1998;46:318-326.
8. Kovacs JA, Vogel S, Albert JM, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med. 1996;335:1350-1356.
9. Carr A, Emery S, Loyd A, et al. Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: A randomised, controlled, multicenter study. J Infect Dis. 1998;178:992-999.
10. Davey RT, Chaitt DG, Albert JM, et al. A randomised trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis. 1999;179:849-858.
11. Levy Y, Capitant C, Houhou S, et al. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: A randomised controlled trial. Lancet. 1999;353:1923-1929.
12. Amo A, Ruiz L, Juan M, et al. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with ≤250/μL CD4+ T cells and undetectable plasma virus load. J Infect Dis. 1999;180:56-60.
13. Zanussi S, Simonelli C, Bortolin MT, et al. Dynamics of provirus load and lymphocyte subsets after interleukin-2 treatment in HIV-infected patients. AIDS Res Hum Retroviruses. 1999;15:97-103.
14. De Paoli P, Zanussi S, Simonelli C, et al. Effects of subcutaneous interleukin-2 therapy on CD4+ subsets and in vitro cytokine production in HIV+ subjects. J Clin Invest. 1997;100:2737-2743.
15. Jacobson EL, Pilaro F, Smith KA. Rational interteukin 2 therapy for HIV positive individuals: Daily low doses enhance immune function without toxicity. Proc Natl Acad Sci USA. 1996;93(19):10405-10410.
16. Schiavon V, Roth P, Bolton WE, Farcet JP, Benusussan A, Boumsell L. Lymphocytes subsets in normal individuals: Analysis by four color immunofluorescence and flow cytometry on whole blood. Tissue Antigens. 1996;48:312-318.
17. Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4+ T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection - A preliminary study. N Engl J Med. 1995;332:567-575.
18. Pape GM, Troye B, Axelsson B, Perlmann P. Simultaneous occurrence of immunoglobulin-dependent and immunoglobulin-independent mechanisms in natural cytotoxicity of human lymphocytes. J Immunol. 1979;122:2251-2260.
19. Olivia A, Kinter AL, Vaccarezza M, et al. Natural killer cells from human immunodeficiency virus-infected individuals are an important source of cc-chemokines and suppress HIV-1 entry and replication in vitro. J Clin Invest. 1998;102:223-231.